v3.25.2
Note 13 - Capital Stock - Outstanding Warrants (Details) - $ / shares
Jun. 30, 2025
Dec. 31, 2024
Number of shares issuable (in shares) 7,242,876 7,242,876
Common Stock Warrant Exercisable on December 2020, One [Member]    
Exercise price (in dollars per share) [1] $ 230  
Number of shares issuable (in shares) [1] 120,375 120,375
Common Stock Warrant Exercisable on December 2020, Two [Member]    
Exercise price (in dollars per share) [2] $ 230  
Number of shares issuable (in shares) [2] 1,229 1,229
Common Stock Warrant Exercisable on June 2023, One [Member]    
Exercise price (in dollars per share) [3] $ 4.6014  
Number of shares issuable (in shares) [3] 150,000 150,000
Common Stock Warrant Exercisable on June 2023, Two [Member]    
Exercise price (in dollars per share) [4] $ 22  
Number of shares issuable (in shares) [4] 2,500,000 2,500,000
Common Stock Warrant Exercisable on June 2023, Three [Member]    
Exercise price (in dollars per share) [5] $ 30  
Number of shares issuable (in shares) [5] 2,500,000 2,500,000
Prefunded Warrant Exercisable on October 2024 [Member]    
Exercise price (in dollars per share) [6] $ 0.001  
Number of shares issuable (in shares) [6] 424,358 424,358
Common Warrant Exercisable on October 2024 [Member]    
Exercise price (in dollars per share) [7] $ 4.82  
Number of shares issuable (in shares) [7] 1,546,914 1,546,914
[1] Represents 120,375 shares of Common Stock underlying warrants to purchase one-fortieth (1/40) of one share of Common Stock, issued during Tottenham’s initial public offering. We may redeem the outstanding warrants at $0.01 per warrant if the last sales price of our Common Stock equals or exceeds $330.00 per share for any 20 trading days within a 30-trading day period. As of June 30, 2025 and December 31, 2024, no warrants had been exercised.
[2] Represents 1,229 shares of Common Stock underlying warrants to purchase one-fortieth (1/40) of one share of Common Stock, issued to the financial advisor and lead underwriter of Tottenham’s initial public offering upon their exercise of a unit purchase option in July 2021. As of June 30, 2025 and December 31, 2024, no warrants had been exercised.
[3] Represents 150,000 shares of Common Stock underlying the 2023 Avenue Warrant, issued pursuant to the Second Amendment (see Note 8). As of June 30, 2025 and December 31, 2024, the warrant had not been exercised.
[4] Represents 2,500,000 shares of Common Stock underlying the Tranche A Warrants to purchase one share of Common Stock, issued in our June 2023 public equity offering. The Tranche A Warrants expire on the earlier of (i) sixty (60) days following the date of our public announcement that an NDA for CNM-Au8 has been accepted by the FDA, or (ii) June 16, 2026. As of June 30, 2025 and December 31, 2024, no warrants had been exercised.
[5] Represents 2,500,000 shares of Common Stock underlying the Tranche B Warrants to purchase one share of Common Stock, issued in our June 2023 public equity offering. The Tranche B Warrants expire on the earlier of (i) sixty (60) days following the date of our public announcement that an NDA for CNM-Au8 has been approved by the FDA, or (ii) June 16, 2030. As of June 30, 2025 and December 31, 2024, no warrants had been exercised.
[6] Represents 424,358 shares of Common Stock underlying the 2024 Pre-Funded Warrants to purchase one share of Common Stock, issued in our October 2024 public equity offering. As of June 30, 2025 and December 31, 2024, 17,626 warrants had been exercised for nominal proceeds.
[7] Represents 1,546,914 shares of Common Stock underlying the 2024 Common Warrants to purchase one share of Common Stock, issued in our October 2024 public equity offering. As of June 30, 2025 and December 31, 2024, no warrants had been exercised.